Unlearn is a science-first company that has created the first machine learning platform for populating Intelligent Control Arms with perfectly matched Digital Twins.
Unlearn accelerates clinical trials by supplementing control groups with synthetic patient data generated using AI, that helps in reducing the time to develop new medicines, enabling healthcare companies to sooner provide patients in need with life-saving therapies.
Unlearn.AI was founded in 2017 by Jonathan Walsh, Aaron Smith, and Charles Fisher. The company is headquartered in San Francisco, California.
Unlearn.AI uses an Intelligent Control Arm in a trial enables sponsors to reduce the number of subjects who receive a placebo.
Unlearn.AI's DiGenesis platform is first being applied to neurological diseases, specifically Alzheimer’s Disease and Multiple Sclerosis, where effective treatment options remain an elusive goal and it has been hard to build clinical trials around patients with already-impacted health.
Unlearn.AI's each subject in a trial with an Intelligent Control Arm is assigned a perfectly matched Digital Twin that describes what would have happened if the subject had received a placebo. By acting as counterfactuals, Digital Twins provide the necessary evidence to understand how each subject in a trial responded to the experimental therapy.
Unlearn.AI is backed by 8VC, DCVC, DCVC Bio, Mubadala Capital Ventures and others. The company raised $12M in a Series A round on April 20, 2020. This brings Unlearn.AI's total funding to $16.8M to date.